News & Updates

Show Multimedia Only
Fracture risk not higher with SGLT2 vs DPP4 inhibitors

Fracture risk not higher with SGLT2 vs DPP4 inhibitors

19 Feb 2023

The use of sodium-glucose transporter 2 (SGLT2) inhibitors among patients with diabetes does not pose an increased risk of developing fractures as compared with dipeptidyl-peptidase 4 (DPP4) inhibitors, and this is true across estimated glomerular filtration rate (eGFR) and albuminuria categories, as shown in a study.

19 Feb 2023